Wegovy for Teens: Reading the WHO Guideline Line by Line and What It Changes in the Clinic

If you're searching for Wegovy for teens, you've probably seen headlines about a WHO guideline and plenty of commentary around it. This post takes a more careful route. It shows you how to read the guideline's scope and strength, what the adolescent trial actually measured, and which questions to bring to the pediatrician.

What the WHO guideline says, in plain language

The World Health Organization has issued a guideline on GLP-1 therapies for obesity. It tells health systems and clinicians what to consider. It does not register a medicine. Approval in each country belongs to the national regulator, so a WHO recommendation never changes a product's label on its own. Copy the exact official title from the cover of the document before you cite it.

Start with the scope section, because it defines who the panel meant to cover. Check three things there: the age range, the condition being treated, and whether adolescents are named directly. Then find the recommendation itself and note whether the wording for young people is strong or conditional. Quote that wording exactly. Paraphrasing a strength is where most misreadings begin.

How WHO grades a recommendation

WHO uses two strengths. A strong recommendation means the panel judged that the benefits clearly outweigh the harms for most people in that situation. A conditional recommendation means the balance depends more on context, such as the patient's values, the cost of treatment, and how easily it can be accessed. For a doctor, a strong recommendation sets a default. For a health manager, it supports coverage decisions. For a family, a conditional recommendation means the answer will come from a conversation, not a rule.

Certainty of evidence is a separate question. The GRADE approach, which WHO uses, rates certainty as high, moderate, low, or very low. Certainty describes how much you can trust the estimates. It does not describe how big the effect is. A panel can be fairly confident that a drug lowers weight and still issue a conditional recommendation, because side effects, cost, or patient preferences pull the decision another way. The evidence table behind each recommendation shows how the panel weighed benefits, harms, resource use, and values. If the grading language feels slippery, OzemBlog's guide to reading guideline strength walks through the same logic with a checklist you can take to the clinic.

A conditional recommendation asks more of the clinician, not less. Each patient needs a personal weighing of benefits, side effects, cost, and what the family wants. Treat the word conditional as a signal to plan a longer visit.

What the adolescent evidence actually covers

The main randomized trial in adolescents with obesity is STEP TEENS, published in the New England Journal of Medicine in 2022 (DOI 10.1056/NEJMoa2208601). It enrolled young people aged 12 to 17 and compared once-weekly semaglutide 2.4 mg with placebo. The treatment period was 68 weeks, and the trial included 201 adolescents. The study measured changes in BMI, body weight, and several metabolic markers. Read the results tables in the paper for the exact values, instead of relying on summaries.

It did not answer several questions. Final adult height, long-term safety beyond the follow-up window, mental health in detail, and what happens after treatment stops all fall outside what this trial could tell us. Those gaps matter because evidence in adolescents is thinner than in adults. Fewer participants and shorter follow-up mean wider uncertainty around every estimate. Growth and puberty add another layer, since results in adults do not automatically predict what happens during a growth spurt. Panels often rate certainty lower for younger populations for exactly these reasons.

What clinicians check before prescribing

Expect a careful workup before any prescription. The clinician should calculate BMI and place it on an age- and sex-specific percentile chart. The WHO growth reference for children and adolescents aged 5 to 19 is the standard tool for this (WHO growth reference data for 5 to 19 years). An adult cut-off alone is not enough. Next comes the search for comorbidities such as high blood pressure, abnormal lipids, fatty liver, or insulin resistance. The team also notes pubertal stage and growth history, because these shape how urgent treatment is and how closely to monitor.

Screening should also cover personal or family history of eating disorders, symptoms of depression, and every other medication the teen takes. Dose increases often bring gastrointestinal side effects, so ask how the team plans to adjust the dose and which symptoms you should report between visits. The monitoring schedule belongs in the guideline's recommendations section, so check it there rather than relying on a secondhand summary.

Medication is rarely the whole plan. Pediatrics, pediatric endocrinology, nutrition, and psychology work best as a team. Lifestyle change stays at the base of treatment. An injection can help, but it doesn't replace family routines, sleep, physical activity, and food support.

Open questions and gaps

Several gaps stand out. Long-term safety is the biggest one. Effects on growth and final height come next. Pancreatitis and gallstones need careful attention in young people, and the data on them remain limited. We also know little about what happens after stopping, including how much weight returns and whether a maintenance plan holds. A good guideline names these gaps openly. Look for any list of ongoing research in the document and note which outcomes those studies target, since that list shows where research priorities sit. Families who want a plain-language starting point can also browse the questions about semaglutide that this blog has been answering.

Where Brazil fits

A WHO recommendation does not change the Brazilian label. What matters here is the registration held with Anvisa. Open the official consultation portal (Anvisa's drug consultation portal), find the Wegovy label, and read the indication text. Check whether it covers adolescents and under which conditions, then note the update date shown on the record.

When a prescription falls outside the approved indication, it is off-label use. The Brazilian Medical Code of Ethics (Resolução CFM nº 2.217/2018) places responsibility on the physician who prescribes, so the medical record should explain the clinical reasoning, the alternatives considered, the evidence relied on, the conversation with the family about risks, and the monitoring plan. Public system coverage is a separate decision with its own rules, and other posts on this blog cover access and costs, so that analysis isn't repeated here.

Questions to bring to the pediatric appointment

Bring a short list so the visit stays focused. Useful questions include:

• What is my child's BMI percentile for age and sex, and how was it measured?
• Does my child have related conditions, and what is the plan beyond the medication for food, activity, and sleep?
• Which symptoms need an immediate call, and how will the team decide whether to stop or continue treatment?

The WHO guideline is a starting point for that conversation, not a shortcut around it. Each teen is different, and so are each family's goals. If something stays unclear after the visit, check the question section of OzemBlog before the next appointment so you walk in with a sharper list.

FAQ

Is Wegovy approved for teens?

It depends on the country and its current label. WHO guidance does not approve products. In Brazil, the indication text in Anvisa's consultation portal defines the population the label covers.

Does the WHO guideline mean every teen with obesity should take Wegovy?

No. A recommendation applies to a defined population and carries a specific strength. Read the scope and the strength, then discuss your child's situation with a clinician who can weigh the individual factors.

What does a conditional recommendation mean for my family?

It means the decision depends on context, including the teen's health profile, costs, and preferences. Expect a detailed conversation before anything starts, and ask what would change the plan.

What is still unknown about semaglutide in teens?

Long-term safety, effects on final height, outcomes after stopping, and rarer risks such as pancreatitis and gallstones all need more data in young people.

Sources

• World Health Organization, publications library (WHO guideline on GLP-1 therapies for obesity)
• WHO growth reference data for 5 to 19 years
• GRADE Working Group, grading of recommendations, assessment, development and evaluation
• Weghuber D, et al. Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS), New England Journal of Medicine, 2022
• Anvisa, Agência Nacional de Vigilância Sanitária
• Anvisa, consulta de bulas de medicamentos
• Conselho Federal de Medicina, Código de Ética Médica (Resolução CFM nº 2.217/2018)